Compare Gilead Sciences, Inc. (GILD) vs KLA Corp. (KLAC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs KLA Corp. — how do they compare? Gilead Sciences, Inc. trades at $147 (market cap $182.09B), while KLA Corp. trades at $201.27 (market cap $256.86B). The key difference: KLA Corp. is the larger of the two by market cap, and Gilead Sciences, Inc. pays the higher dividend (2.23%). Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and KLA Corp. for 60 Days on average.
| GILD | KLAC | |
|---|---|---|
Market Cap | $182.09B | $256.86B |
Volume | 4,960,247 | 7,016,455 |
Sector | Health | Technology |
52-Week High | $155.80 | $301.71 |
52-Week Low | $116.74 | $98.28 |
Typical Hold Time | 111 Days | 60 Days |
Enterprise Value | $205.15B | $258.11B |
Dividend Yield | 2.23% | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $146.85, up 1.82% with bullish technical signals and strong analyst support. Recent earnings beat expectations in three consecutive quarters, though Q2 showed a significant loss. The company maintains robust operating cash flow of $10.02B (2025) and expanded HIV prevention access through a major PAHO partnership. Valuation metrics show a P/E of 17.84 and P/S of 6.02, with revenue growth from $29.44B (2025) to projected $30.5B (2026).
Outlook remains positive with 65% analyst buy ratings and $151.57 consensus target, though risks include negative net income margin (-10.64%) and high debt levels. The stock offers dividend income ($0.82 upcoming) and pipeline catalysts in oncology/HIV, but investors should monitor earnings volatility and competitive pressures in biopharma.
KLA Corporation (KLAC) trades at $196.72, down 0.37% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported revenue of $12.16 billion in 2025, with net income of $4.06 billion and a robust net margin of 33.41%. Recent earnings beats and a significant backlog driven by AI demand highlight operational strength, while analyst consensus remains strongly positive with a $223.88 price target.
The outlook for KLAC is favorable, supported by AI-led growth in semiconductor equipment demand and solid financials, though high valuation multiples and competitive pressures pose risks. Upside potential exists if the company continues to exceed earnings expectations and capitalize on industry tailwinds, but investors should monitor margin trends and debt levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About KLA Corp.
KLA designs and manufactures yield-management and process-monitoring diagnostic and control systems for the semiconductor manufacturing industry. The systems are used to analyze the manufacturing process at various steps in a semiconductor's development. The firm's laser-scanning products are used for wafer qualification, process monitoring, and equipment monitoring. KLA also provides inspection tools and systems for optical metrology and e-beam metrology.
Read more on KLAC →
